Benzinga··Soligenix, Inc.Soligenix's HyBryte Shows Promise Against Cutaneous Lymphoma at 2026 Workshop
Soligenix's HyBryte™ cutaneous lymphoma therapy shows positive results ahead of 2026 presentation, with FDA awarding $2.6M development grant.
SNGXPhase 3 clinical trialFDA approval